On Monday, Beam Therapeutics Inc (NASDAQ: BEAM) was 3.86% up from the session before settling in for the closing price of $25.38. A 52-week range for BEAM has been $20.84 – $49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 54121.88% over the last five years. When this article was written, the company’s average yearly earnings per share was at -174.66%. With a float of $72.66 million, this company’s outstanding shares have now reached $82.56 million.
The firm has a total of 436 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 12.25%, while institutional ownership is 81.91%. The most recent insider transaction that took place on Jan 02 ’25, was worth 30,628. In this transaction Chief Legal Officer of this company sold 1,241 shares at a rate of $24.68, taking the stock ownership to the 102,968 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, Finance and Treasurer sold 1,117 for $24.68, making the entire transaction worth $27,568. This insider now owns 43,814 shares in total.
Beam Therapeutics Inc (BEAM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -174.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.84 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Analysing the last 5-days average volume posted by the [Beam Therapeutics Inc, BEAM], we can find that recorded value of 1.0 million was lower than the volume posted last year of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 24.34%. Additionally, its Average True Range was 1.77.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 46.84%, which indicates a significant increase from 40.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.31% in the past 14 days, which was lower than the 67.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.07, while its 200-day Moving Average is $25.57. Now, the first resistance to watch is $27.32. This is followed by the second major resistance level at $28.28. The third major resistance level sits at $29.56. If the price goes on to break the first support level at $25.08, it is likely to go to the next support level at $23.80. Should the price break the second support level, the third support level stands at $22.84.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are 82,806K outstanding shares of the company, which has a market capitalization of 2.18 billion. As of now, sales total 377,710 K while income totals -132,530 K. Its latest quarter income was 14,270 K while its last quarter net income were -96,670 K.
